Skip to main content Help with accessibility Skip to main navigation

Tiotropium HandiHaler 18microgram inhalation powder

Indication

COPD

MHRA Drug Safety Update - Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial

Green

Brand:

Spiriva

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Respiratory system

Background

Tiotropium 18mcg once daily via HandiHaler® remains the preferred LAMA based on its greater body of evidence in moderate, severe and very severe COPD and in patients with a history of exacerbations.

In line with the Medicines and Healthcare products Regulatory Agency guidance released on the 12th February 2015, LMMG reminds prescribers to review the risk of cardiovascular side effects when prescribing tiotropium (via Respimat or Handihaler) to patients with certain cardiac conditions, who were excluded from clinical trials of tiotropium (including TIOSPIR). See link below to the trial via the MHRA website.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

COPD Guideline Version 1.9

COPD Bronchodilator Evidence Review Final Recommendation Following LMMG Website Update

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Pending
Green
Green
Pending
Green
Green
Green
Pending
What do the colours mean?

Last Updated: 01 - Mar - 2015